Feb 29 |
Cardiff Oncology GAAP EPS of -$0.93 beats by $0.08, revenue of $0.48M beats by $0.2M
|
Feb 29 |
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
|
Feb 29 |
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
|
Feb 29 |
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
|
Feb 29 |
Earnings Scheduled For February 29, 2024
|
Feb 28 |
Cardiff Oncology Q4 2023 Earnings Preview
|
Feb 28 |
Cardiff Oncology Earnings Preview
|
Feb 26 |
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
|
Feb 22 |
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
|
Jan 17 |
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
|